|  Sign up!  


Return to Course Listing



CME: Heart Failure: Best Practices, Emerging Therapies, and Barriers to Care


Program Description / Statement of Need:

In this online CME self-learning program:


Chronic heart failure (HF) is a widespread and costly condition, which affects nearly 6 million people in the U.S.  HF is the reason for more than 1 million hospitalizations. There are numerous guidelines for the treatment of heart failure, some of which are now dated. HCPs are often unable to keep up with the steady publishing of literature and evolution of clinical practice; that may be true in particular for PCPs in the treatment of HF. There have also been a number of emerging agents, some approved, some investigational, that have implications for clinical practice, and the clinician may need guidance in determining their place, current or anticipated. There are also less common clinical circumstances in which some therapeutic mechanisms may be preferential over others. There are other barriers as well that may be ameliorated, like suboptimal prescribing, or be helpful in guiding patient-provider interactions, such as racial disparities in care, that CME programming may address.





Introduction, Disclosures

Orienting the clinician to the scope of the problem: epidemiology of and risk factors for HF

  • Statistics – snapshots and trends
  • Gender and racial differences
  • Comorbid diseases (diabetes, vascular disease, hypertension)
  • Risk factors, modifiable and non-

 Updates in diagnostics, pathophysiology, and prognostics [Learning Objective #1]

  • Onset (History and physical)
  • Differential diagnosis and diagnostic criteria
  • Compensatory mechanisms

Treatment of HF

  • Latest evidence supporting when to start therapy [Learning Objective #2]
  • Recent advances in pharmacotherapy therapy and emerging roles [Learning Objective #3]
  • Best practice: putting it all together
  • Patient cases [Learning Objectives #2, 3, & 4]

Barriers to optimal care in patients with HF [Learning Objective #5]

  • Medication non-adherence, adverse effects, and drug-drug interactions
  • The clinician’s role in the patient
  • Relationship triad of healthcare professional, patient, and caregiver, including racial disparity considerations

Summary, conclusions, and best practice recap


Target Audience:

Healthcare professionals specializing in: cardiology, internal medicine, or those who otherwise commonly care for patients with HF or who frequently encounter them or their caregivers in practice.

Program Objectives:

By the end of the session the participant will be able to:

    • Describe the pathophysiology of HF.
    • Identify the present treatment options currently available for management of HF and apply them to patient cases using evidence-based medicine.
    • Describe emerging drug therapies in the treatment of HF
    • Evaluate a treatment plan for a specific patient based on degree of HF to optimize safety and efficacy, suggesting modifications for improvement.
    • Describe barriers to care in HF.


    This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through ScientiaCME. ScientiaCME is accredited by the ACCME to provide continuing medical education for physicians.



    Release Date: December 29, 2015
    Expiration Date: December 29, 2017

    Faculty: Luanda Grazette MD

    Faculty Disclosure and Resolution of COI:

     As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.


    Faculty Disclosure:  Luanda Grazette, MD


    Disclosures of Educational Planners: Charles Turck, PharmD is an officer and part owner of ScientiaCME, LLC.


    Commercial Support Disclosure: This program is supported by an educational grant from AMGEN


    Viewing Instructions



    Windows 2000 or above
    Internet Explorer 5.5
    Adobe Acrobat Reader*

    Mac OS 10.2.8
    Adobe Acrobat Reader*
    Internet Explorer is not supported on the Macintosh


    *Required to view Printable PDF Version


    Privacy Policy



    -Read the learning objectives and faculty disclosures above

    -Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowedge gained by participating in this CME activity.

    -View the on-line program. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.

    -Take the post-test

    -Complete the program evaluation and CME registration. A CE certificate will be emailed to you.

    Perform Pre-Test (optional)
    Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.

    Download the Presentation (optional)


    View the online program


    Perform Post-Test

    Complete the Symposium Evaluation and Request CE Certificate

This program is supported by an educational grant from AMGEN


Your feedback is important to us. Please Contact Us to let us know how to make this site better. Thank you.